Tirzepatide vs Ozempic: Mechanism, Results, Cost

Key takeaways

• Ozempic is semaglutide, labeled for type 2 diabetes at up to 2 mg a week. Tirzepatide is sold as Mounjaro for diabetes and Zepbound for weight. The fair comparison is Ozempic against Mounjaro.
• In SURPASS-2, tirzepatide 5, 10 and 15 mg lowered HbA1c by 2.01, 2.24 and 2.30 points over 40 weeks versus 1.86 with semaglutide 1 mg, with 1.9 to 5.5 kg more weight loss and similar nausea rates.
• Ozempic has more hard-outcome evidence: fewer cardiovascular events than placebo (6.6% versus 8.9%) and a 24% lower risk of major kidney events in diabetes with kidney disease. Tirzepatide was non-inferior to dulaglutide on cardiovascular events, enough for a Mounjaro indication in August 2026.
• Ozempic is not approved for weight loss. Used that way, it delivers less drug than Wegovy, and in real-world records people lost about 7 percentage points more at a year on tirzepatide.
• Cash prices differ sharply by brand: Ozempic $350 a month on TrumpRx, Mounjaro about $1,112 at list, Zepbound $299 to $449 through Lilly's self-pay program.

Tirzepatide is more effective than Ozempic at lowering blood sugar and weight; Ozempic has more proof of protecting the heart and kidneys. Ozempic is semaglutide labeled for type 2 diabetes, so the fair matchup is Mounjaro, tirzepatide's diabetes brand, and the trial that tested them is SURPASS-2. Mechanism in one line: semaglutide activates the GLP-1 receptor, tirzepatide activates GLP-1 and GIP, as semaglutide vs tirzepatide: the real differences explains. For the weight-loss brands, see the parent comparison, Zepbound vs Wegovy.

Tirzepatide vs Ozempic at a glance

Sources: (Ozempic label) (Mounjaro label) and the trials below.

Diabetes results: SURPASS-2

SURPASS-2 randomized 1,879 adults with type 2 diabetes on metformin (mean HbA1c 8.28%, mean weight 93.7 kg) to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg weekly for 40 weeks. HbA1c fell 2.01, 2.24 and 2.30 percentage points with tirzepatide against 1.86 with semaglutide; all three tirzepatide doses were superior. Tirzepatide also produced 1.9, 3.6 and 5.5 kg more weight loss. Nausea affected 17 to 22% on tirzepatide versus 18% on semaglutide, diarrhea 13 to 16% versus 12%, vomiting 6 to 10% versus 8%. Serious low blood sugar (under 54 mg/dL) was rare, 0.2 to 1.7% versus 0.4%, and serious adverse events occurred in 5 to 7% versus 3% (Frías 2021).

Three limits matter. The trial was open-label and Lilly-funded. It used semaglutide 1 mg, while the current Ozempic label goes to 2 mg for people who need more glucose control, a dose never tested against tirzepatide. And at 40 weeks it measured glucose and weight, not heart attacks or kidney failure.

Heart and kidneys: different questions, different comparators

Ozempic against placebo. In SUSTAIN-6, 3,297 people with type 2 diabetes at high cardiovascular risk took semaglutide 0.5 or 1 mg or placebo for two years. Cardiovascular death, heart attack or stroke occurred in 6.6% versus 8.9% (hazard ratio 0.74), driven mainly by fewer strokes; cardiovascular deaths were similar. Retinopathy complications were more common on semaglutide (hazard ratio 1.76), which is why both labels warn about diabetic eye disease (Marso 2016). In FLOW, 3,533 people with diabetes and chronic kidney disease took semaglutide 1 mg or placebo for a median of 3.4 years; major kidney events, including kidney failure, halving of kidney function and cardiovascular death, were 24% less likely (hazard ratio 0.76), and death from any cause 20% less likely (Perkovic 2024). Both results are Ozempic indications (Ozempic label).

Tirzepatide against an active drug. SURPASS-CVOT randomized 13,299 people with diabetes and atherosclerotic disease to tirzepatide up to 15 mg or dulaglutide 1.5 mg, a GLP-1 drug already shown to reduce cardiovascular events. The primary outcome occurred in 12.2% versus 13.1% (hazard ratio 0.92): non-inferior, not superior (Nicholls 2025). All-cause death was lower on tirzepatide (8.5% versus 10.1% in the label's analysis), but the label flags that comparison as not controlled for multiple testing (Mounjaro label).

So there is no head-to-head outcome trial between Ozempic and tirzepatide. Ozempic beat placebo; tirzepatide matched a drug that had beaten placebo. For someone whose main worry is a second heart attack or failing kidneys, Ozempic's label states more; for someone whose main problem is glucose and weight, tirzepatide does more.

Off-label weight use

Ozempic is not approved for weight loss; the same molecule for that purpose is Wegovy, which goes to 2.4 mg and up to 7.2 mg, while Ozempic stops at 2 mg. Prescribing Ozempic for weight alone is off label, and coverage for diabetes brands is generally tied to a diabetes diagnosis. Our semaglutide dosage chart shows both schedules.

The best evidence on how the diabetes-labeled products compare for weight comes from health records. Among 18,386 propensity-matched adults with overweight or obesity (52% with type 2 diabetes) who started the diabetes-labeled formulations of tirzepatide or semaglutide in 2022 and 2023, tirzepatide users were more likely to lose at least 5%, 10% and 15%, and lost 2.4, 4.3 and 6.9 percentage points more at 3, 6 and 12 months. Gastrointestinal adverse events were similar, and more than half of each group had stopped by the end of follow-up (Rodriguez 2024). It is an observational study, so prescribing differences can bias it, but its direction matches the randomized trial in obesity, where tirzepatide 10 or 15 mg produced 20.2% weight loss versus 13.7% on semaglutide 1.7 or 2.4 mg (Aronne 2025).

Side effects

The pattern is the same: nausea, diarrhea, vomiting and constipation, worst during dose increases. On Ozempic's label, nausea affected 15.8% at 0.5 mg and 20.3% at 1 mg versus 6.1% on placebo, vomiting 5.0% and 9.2% versus 2.3%, and 3.1 to 3.8% stopped for gastrointestinal effects versus 0.4% (Ozempic label). Head to head in SURPASS-2, the rates were close (above). Differences worth knowing: tirzepatide causes more injection-site reactions; it reduces the reliability of contraceptive pills for four weeks after starting and after each dose increase; and both drugs raise the risk of low blood sugar when combined with insulin or a sulfonylurea, whose doses usually need to come down. Both carry the boxed warning on thyroid C-cell tumors seen in rodents. Our GLP-1 side effects guide covers the full list.

Costs in October 2026

Prices are from our cost guide and tirzepatide cost guide. For type 2 diabetes, both drugs are commonly covered by commercial plans and Medicare Part D under each plan's formulary rules, which usually beats any cash price. Paying cash for tirzepatide, the Zepbound label is far cheaper than Mounjaro for the same molecule. Compounded versions are legal only for a documented individual need; see compounded semaglutide vs tirzepatide.

Who each fits

Dose schedules are on the labels; your prescriber sets yours, and with any compounded vial the peptide calculator converts milligrams to syringe units.

Bottom line

Against Ozempic, tirzepatide lowers HbA1c and weight more, with similar stomach side effects. Ozempic has placebo-controlled proof of fewer cardiovascular events and slower kidney decline in type 2 diabetes; tirzepatide has proof it is at least as good as dulaglutide on the heart. For weight without diabetes, compare the weight-loss brands instead, Zepbound and Wegovy.

Frequently asked questions

+−Is tirzepatide better than Ozempic?

For blood sugar and weight, yes in the one direct comparison. In SURPASS-2, 1,879 adults with type 2 diabetes lowered HbA1c by 2.01 to 2.30 percentage points on tirzepatide 5 to 15 mg versus 1.86 on semaglutide 1 mg (an Ozempic dose) over 40 weeks, and lost 1.9 to 5.5 kg more. Ozempic has the longer outcome record: placebo-controlled trials showed fewer cardiovascular events and slower kidney decline. Tirzepatide's heart trial showed it was as good as another GLP-1 drug, dulaglutide.

+−Can I take Ozempic for weight loss?

Only off label. Ozempic is approved for type 2 diabetes, at doses up to 2 mg a week; the same drug for weight management is Wegovy, at 2.4 mg and up to 7.2 mg. A prescriber can write Ozempic off label, but coverage for diabetes brands is generally tied to a diabetes diagnosis. In a large records study, people with overweight or obesity using the diabetes-labeled formulations lost more on tirzepatide than on semaglutide, about 7 percentage points more at 12 months.

+−Is Ozempic a peptide?

Yes. Semaglutide, the active ingredient of Ozempic, Wegovy and Rybelsus, is a modified version of the human hormone GLP-1, a 31-amino-acid peptide, with a fatty-acid chain that makes it last about a week. Tirzepatide (Mounjaro, Zepbound) is also a peptide. That is why both are injected and why the semaglutide pill needs an absorption enhancer.

+−Is tirzepatide the same as Mounjaro?

Mounjaro is tirzepatide, Eli Lilly's brand for type 2 diabetes. Zepbound is the same molecule at the same doses, labeled for weight management and sleep apnea. Vials sold as research-grade tirzepatide are not Mounjaro; they are unapproved products that FDA warned sellers about in 2026.

+−What are Ozempic's competitors?

Among weekly injections for type 2 diabetes, the main ones are tirzepatide (Mounjaro) and dulaglutide (Trulicity), the comparator in tirzepatide's heart trial. Oral options include semaglutide tablets (Rybelsus and Ozempic tablets). For weight management the semaglutide brand is Wegovy and the tirzepatide brand is Zepbound; Foundayo is an oral GLP-1 pill for weight.

+−Who should not take Mounjaro or Ozempic?

Both labels contraindicate them with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or a prior serious allergic reaction to the drug. Neither is for type 1 diabetes. Severe gastroparesis, pregnancy, a history of pancreatitis, diabetic retinopathy and use with insulin or a sulfonylurea all call for caution or monitoring, and tirzepatide reduces the reliability of contraceptive pills around each dose increase.

+−Can you switch from Ozempic to Mounjaro?

Yes, prescribers do, but neither label has a conversion chart, and both say not to combine the drug with another GLP-1 product. Mounjaro's label schedule starts at 2.5 mg weekly and rises by 2.5 mg no sooner than every four weeks if more glucose control is needed. Where to start after Ozempic is a clinical judgment.

Sources

1. StudyFrías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021;385:503-15. (2021)
2. StudyMarso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-44. (2016)
3. StudyPerkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-21. (2024)
4. StudyNicholls SJ et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med 2025;393:2409-20. (2025)
5. StudyRodriguez PJ et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med 2024;184:1056-64. (2024)
6. StudyAronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. (2025)
7. LabelNovo Nordisk. Ozempic (semaglutide) injection: prescribing information, revised June 2026 (DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79). (2026)
8. LabelEli Lilly. Mounjaro (tirzepatide) injection: prescribing information, revised August 2026 (DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0). (2026)